Literature DB >> 9928954

Phosphoinositide 3-kinase and integrin signalling are involved in activation of Bruton tyrosine kinase in thrombin-stimulated platelets.

M Laffargue1, J M Ragab-Thomas, A Ragab, J Tuech, K Missy, L Monnereau, U Blank, M Plantavid, B Payrastre, P Raynal, H Chap.   

Abstract

Bruton tyrosine kinase (Btk) plays a crucial role in the differentiation of B lymphocytes and belongs to the group of Tec kinases, which are characterised by the presence of a pleckstrin homology domain. Here we show that Btk is activated and undergoes tyrosine phosphorylation upon challenge of platelet thrombin receptor, these responses requiring engagement of alphaIIb/beta3 integrin and phosphoinositide 3-kinase activity. These data unravel a novel signalling pathway involving Btk downstream of an adhesive receptor via a complex regulation implicating the products of phosphoinositide 3-kinase, which might act to anchor Btk at the membrane.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9928954     DOI: 10.1016/s0014-5793(98)01680-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  8 in total

1.  Platelet alpha IIb-beta 3 integrin engagement induces the tyrosine phosphorylation of Cbl and its association with phosphoinositide 3-kinase and Syk.

Authors:  A Saci; F Rendu; C Bachelot-Loza
Journal:  Biochem J       Date:  2000-11-01       Impact factor: 3.857

2.  Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets.

Authors:  Bhanu Kanth Manne; Rachit Badolia; Carol Dangelmaier; Johannes A Eble; Wilfried Ellmeier; Mark Kahn; Satya P Kunapuli
Journal:  J Biol Chem       Date:  2015-03-12       Impact factor: 5.157

3.  Phosphatidylinositol 3,4,5-trisphosphate regulates Ca(2+) entry via btk in platelets and megakaryocytes without increasing phospholipase C activity.

Authors:  J M Pasquet; L Quek; C Stevens; R Bobe; M Huber; V Duronio; G Krystal; S P Watson
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

Review 4.  Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.

Authors:  Uddalak Bharadwaj; Moses M Kasembeli; Prema Robinson; David J Tweardy
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

Review 5.  Vesicular trafficking and signaling for cytokine and chemokine secretion in mast cells.

Authors:  Ulrich Blank; Iris Karina Madera-Salcedo; Luca Danelli; Julien Claver; Neeraj Tiwari; Elizabeth Sánchez-Miranda; Genaro Vázquez-Victorio; Karla Alina Ramírez-Valadez; Marina Macias-Silva; Claudia González-Espinosa
Journal:  Front Immunol       Date:  2014-09-22       Impact factor: 7.561

Review 6.  Targets for Ibrutinib Beyond B Cell Malignancies.

Authors:  A Berglöf; A Hamasy; S Meinke; M Palma; A Krstic; R Månsson; E Kimby; A Österborg; C I E Smith
Journal:  Scand J Immunol       Date:  2015-09       Impact factor: 3.487

Review 7.  Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?

Authors:  Przemysław J Kotyla; Małgorzata Engelmann; Joanna Giemza-Stokłosa; Bartosz Wnuk; Md Asiful Islam
Journal:  Int J Mol Sci       Date:  2021-02-28       Impact factor: 5.923

8.  Mast cells as cellular sensors in inflammation and immunity.

Authors:  Walid Beghdadi; Lydia Célia Madjene; Marc Benhamou; Nicolas Charles; Gregory Gautier; Pierre Launay; Ulrich Blank
Journal:  Front Immunol       Date:  2011-09-06       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.